Hematological Oncology · 2007 · 38 citations · 9 references
MedicineOncologyRadiologyDiagnostic ImagingDiagnostic RadiologyNeuroradiologyLymphoma ImagingNeuro-oncologic ImagingNeuro-oncology ImagingNeurologic ImagingPositron Emission TomographyTumor Imaging18F-fluorodeoxyglucose ImagingNon-hodgkin Lymphoma ImagingOncologic Pet ImagingPet-computed TomographyPositron Emission Tomography DiagnosisPositron Emission Tomography FindingsPositron Emission Tomography Response AssessmentTreatment Response Criteria
Neurolymphomatosis (NL) is lymphomatous infiltration of peripheral nerves, and is an uncommon manifestation of non-Hodgkin's lymphoma (NHL). Although nerve biopsy is the main method for histological diagnosis, a blind nerve biopsy may not be diagnostic. While CT and MRI have been used to detect NL, recent reports demonstrated the benefit of integrated positron emission tomography (PET) using F18-2-fluoro-2-deoxy-D-glucose (FDG) combined with computed tomography (CT). We described the utility of FDG PET-CT in this uncommon subgroup of NHL where it can assist in establishing the diagnosis, the potential to guide sites for biopsy and in the assessment of response to therapy.
9
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Lale Kostakoğlu, Morton Coleman, John P. Leonard et al. · PubMed · 2002 · 367 citations
Medicine, Nuclear Medicine, Oncology +17
Joachim M. Baehring · Neuro-Oncology · 2003 · 252 citations
Yuliya Jhanwar, David J. Straus · PubMed · 2006 · 116 citations